SCHEMBL5423396

SCHEMBL5423396

CNC(=O)c1cc(Oc2ccc(C(=O)Nc3ccccc3O)cc2)ccn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 12/20 0.61
▸ KDR P35968 7/20 0.61
▸ MAPK14 Q16539 2/20 0.54
▸ RAF1 P04049 6/20 0.53
▸ EPHX2 P34913 1/20 0.53
▸ PLK4 O00444 1/20 0.51
▸ AURKA O14965 1/20 0.51
▸ MAPK13 O15264 1/20 0.51
▸ JAK2 O60674 1/20 0.51
▸ MAP4K4 O95819 1/20 0.51
▸ ABL1 P00519 1/20 0.51
▸ LCK P06239 1/20 0.51
▸ FYN P06241 1/20 0.51
▸ LYN P07948 1/20 0.51
▸ RET P07949 1/20 0.51
▸ ROS1 P08922 1/20 0.51
▸ SRC P12931 1/20 0.51
▸ RPS6KB1 P23443 1/20 0.51
▸ EPHA2 P29317 1/20 0.51
▸ TYK2 P29597 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5435644 0.90 KDR (0.57) BRAFKDRMAPK14RAF1PLK4
SCHEMBL5427738 0.87 KDR (0.53) BRAFKDRMAPK14RAF1EPHX2
SCHEMBL5421735 0.87 KDR (0.53) BRAFKDRMAPK14RAF1EPHX2
SCHEMBL19878522 0.83 KDR (0.74) BRAFKDRMAPK14RAF1EPHX2
SCHEMBL19888723 0.81 ABL1 (0.59) BRAFKDRMAPK14RAF1EPHX2
SCHEMBL2746237 0.81 KDR (0.60) BRAFKDRRAF1MET
SCHEMBL18681347 0.80 BRAF (0.70) BRAFKDRMAPK14RAF1EPHX2
SCHEMBL12431980 0.80 NPC1 (0.68) NPC1RAB9AATM
SCHEMBL13603818 0.80 KDR (0.65) BRAFKDRMAPK14RAF1EPHX2
SCHEMBL3590776 0.80 BRAF (0.69) BRAFKDRMAPK14RAF1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2007-06-21 — — US claimed
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2007-06-21 — — US disclosed
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2007-06-21 — — US disclosed
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors TIE1, KDR, FLT1 BRAF 49/4885KDR 2/4885MAPK14 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback